Trustworthy, AI-Powered Skin Cancer Risk Detection
DermaSensor helps busy clinicians evaluate suspicious skin lesions at the point of care, supporting earlier assessment and helping the right patients receive follow-up care sooner.
Expanding Access to Skin Cancer Evaluation
-
Earlier Assessment
Many patients raise skin concerns during routine visits. With immediate lesion assessment available, clinicians can address these concerns on the spot rather than deferring evaluation to future appointments.
-
More Informed Referrals
The DermaSensor device provides additional insight during clinical evaluation, helping clinicians quickly determine which lesions may warrant dermatology referral and which may be safely monitored.
-
Broader Community Reach
In many regions, access to specialty care remains limited. Point-of-care lesion evaluation helps extend skin cancer risk assessment into everyday settings across underserved communities.
-
Improved Patient Reassurance
A quick and reliable skin cancer risk evaluation can help reduce patient anxiety while enabling clearer conversations about whether continued monitoring or further evaluation is appropriate.
By bringing lesion evaluation into routine care, DermaSensor helps expand access to skin cancer risk assessment while supporting timely care pathways and a more reassuring patient experience.
FAQs about Value-Based Care
How does DermaSensor support value-based care initiatives?
By enabling earlier evaluation of suspicious skin lesions at the point of care, the DermaSensor device can help improve access to quick and reliable skin cancer risk assessment and support coordinated referral pathways.
How does earlier lesion evaluation benefit patient outcomes?
The stage at which skin cancer is detected is strongly associated with outcomes. Early clinical evaluation is a key factor in treatment decisions and overall prognosis.
How does the device support coordinated care across healthcare systems?
Clinical studies showed that device use increased physicians’ skin cancer sensitivity by 6% to 9% and reduced missed skin cancer referrals by 30% to 52%, helping clinicians make more informed referral decisions.
What information does the DermaSensor device provide to clinicians?
The device delivers a binary result of “Monitor” or “Investigate Further.” When a lesion receives an “Investigate Further” result, the device also displays a spectral score from 1 to 10, indicating how closely the lesion’s spectral signature resembles malignant lesions observed in clinical studies.
What types of skin cancer does DermaSensor evaluate risk for?
The device is indicated for evaluating lesions suspicious of melanoma, basal cell carcinoma, and squamous cell carcinoma.
How accurate is DermaSensor at detecting skin cancer?
In clinical studies, DermaSensor demonstrated 95.5% sensitivity for detecting all skin cancers, with sensitivity and overall accuracy higher than primary care physicians’ assessments.
Is the device invasive for patients?
No, the device collects non-invasive spectral recordings from the skin surface.
Is DermaSensor FDA-cleared?
Yes, DermaSensor is FDA-cleared via the De Novo pathway and holds Breakthrough Device
designation, the first device of its kind indicated for evaluating all three common skin cancers.
How long does it take to learn how to use the device?
The DermaSensor requires just 15 minutes of total training time.
80-0009.14
